AI-assisted international press reviewPress review

DePuy Synthes Unveils Cutting-Edge Innovations in Trauma Care at OTA 2026

At OTA 2026, DePuy Synthes showcases significant advancements in trauma care, including fracture fixation systems and AI-based surgical assistance technologies, reinforcing its leadership role in the sector. These innovations aim to enhance the management of complex injuries and optimize patient outcomes.

Source: J&j, published under the title "DePuy Synthes Showcases Next-Generation Trauma Innovations a..." - 22 September 2026

American Chemical Society Honors Novartis Researchers for Their Contributions

The American Chemical Society recently awarded honors to researchers from Novartis for their significant contributions in the field of chemistry and pharmaceutical research. These accolades highlight the importance of scientific innovation in the development of new complex molecules and active ingredients, which are essential for the future of health and medical treatments. This recognition underscores the crucial role of pharmaceutical companies in advancing health technologies and their impact on the industry.

Source: Novartis, published under the title "American Chemical Society honors Novartis researchers" - 22 September 2026

CAPLYTA® Shows Rapid Improvement in Manic Symptoms in Phase 3 Study

Preliminary results from a Phase 3 study on CAPLYTA® (lumateperone) indicate a significant reduction in manic symptoms among adults with Type I bipolar disorder, with notable improvements observed as early as the third day of treatment. This advancement could transform the management of manic episodes, providing a promising therapeutic option for patients.

Source: J&j, published under the title "CAPLYTA® (lumateperone) shows significant and rapid improvem..." - 22 September 2026

RDKit: Celebrating 20 Years of Innovation in Computational Chemistry in Darmstadt

The RDKit conference, bringing together over 300 experts, highlights the evolution of computational chemistry tools and their impact on pharmaceutical research. Merck, the event host, emphasizes the importance of collaboration between industry and the open-source community to accelerate scientific innovation.

Source: Merck, published under the title "Computational Chemistry and AI in Chemistry Conference at Me..." - 21 September 2026

Novartis Receives Positive Opinion for Cosentyx® in Treating PMR

The EMA's Committee for Medicinal Products for Human Use has recommended the market authorization of Cosentyx® for the treatment of polymyalgia rheumatica, marking a significant advancement in the treatment of this common inflammatory disease in the elderly. If approved, Cosentyx would be the first interleukin-17A inhibitor in Europe for this condition, providing an alternative to steroid treatments, which are often associated with undesirable side effects. Clinical trial results show a significant improvement in durable remission rates, highlighting the importance of this new therapeutic option.

Source: Novartis, published under the title "Novartis receives positive CHMP opinion for Cosentyx® in pol..." - 19 September 2026

Abbott Declares 411th Consecutive Quarterly Dividend, Reinforcing Leadership

Abbott's board of directors has declared a dividend of 63 cents per share, confirming its leadership position in dividend payments with a continuous increase for 54 years. This dividend will be paid on November 16, 2026, further solidifying Abbott's reputation as a member of the S&P 500 Dividend Aristocrats.

Source: Abbott, published under the title "Abbott Declares 411th Consecutive Quarterly Dividend" - 18 September 2026

FDA Approves Kerendia™ for Chronic Kidney Disease Related to Type 1 Diabetes

Kerendia™ becomes the first treatment approved in over 30 years for adults suffering from chronic kidney disease associated with type 1 diabetes, addressing a crucial need for a high-risk population for kidney failure. This approval is based on positive results from clinical studies, showing a significant reduction in albuminuria, a key indicator of disease progression.

Source: Bayer, published under the title "U.S. FDA approves finerenone for new indication in patients ..." - 17 September 2026

Robigo and Leaps by Bayer: Funding for Innovative Biopesticides

Robigo, with Series A funding led by Leaps by Bayer, is developing microbes designed to combat fungal diseases in crops, providing an economical and effective alternative to chemical products. The ARGO™ platform enables accelerated development, aiming to transform crop protection while supporting a more resilient food system.

Source: Bayer, published under the title "Robigo and Leaps by Bayer Announce Series A Financing to Adv..." - 17 September 2026

Johnson & Johnson Reports Promising Results for NSCLC Treatment

At the World Lung Cancer Conference, Johnson & Johnson unveiled encouraging results from the COPERNICUS study, demonstrating that treatment with RYBREVANT FASPRO and LAZCLUZE could enhance the experience for patients with non-small cell lung cancer. Preliminary data show low rates of adverse events and improved survival, underscoring the importance of innovation in cancer treatment.

Source: J&j - 15 September 2026

GSK Acquires Promising TCE for Multiple Myeloma Treatment

GSK has announced the acquisition of a trispecific TCE targeting T cells and two tumor antigens, promising increased efficacy and safety compared to current TCEs. This program is expected to enter clinical trials in 2027 and aligns with GSK's strategy to enhance its hematology oncology portfolio with differentiated and validated assets.

Source: Gsk, published under the title "GSK to acquire potential best-in-class T cell-engager (TCE) ..." - 15 September 2026

Sanofi and Cheplapharm: A Strategic Partnership for Mature Medicines

Sanofi and Cheplapharm announce the establishment of a strategic partnership that will allow Cheplapharm to acquire 20 mature medicines and three manufacturing sites. This partnership, which builds on a long-standing collaboration, aims to adapt operational models to the specific needs of mature medicines while enabling Sanofi to focus on innovation. The commercial transfer is expected to begin in early 2027, with finalization by the third quarter of the same year.

Source: Sanofi, published under the title "Press Release: Sanofi and Cheplapharm to create new strategi..." - 15 September 2026

AI in Oncology: Untapped Potential According to Johnson & Johnson

A survey by Johnson & Johnson reveals that while most community oncologists believe in AI to enhance care, its usage remains limited. Barriers include a lack of training and infrastructure, necessitating investments to turn this technology into real benefits for patients.

Source: J&j - 15 September 2026

Abbott Reaches $385 Million Settlement Over Infant Formula Recall Claims

Abbott has agreed to pay $385 million to settle claims without admitting fault, following tests that showed no contamination by Cronobacter sakazakii in its unopened products. The CDC also stated that there was no link between the Sturgis plant and reported infection cases, emphasizing that contamination often occurs at home.

Source: Abbott, published under the title "Abbott Reaches Agreement With Department Of Justice To Resol..." - 15 September 2026

RYBREVANT: A Major Breakthrough in Lung Cancer Treatment

The results of the PAPILLON study reveal that the combined treatment of RYBREVANT and chemotherapy offers a median overall survival of 34.3 months for patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations, establishing a new standard in this historically challenging patient population.

Source: J&j - 14 September 2026

Tagrisso: A Major Breakthrough in Treating EGFR-Mutated Lung Cancer

Results from the Phase III ADAURA trial reveal that Tagrisso provides a durable eight-year survival benefit for patients with EGFR-mutated non-small cell lung cancer, reinforcing its status as a standard treatment in this indication. Nearly 80% of treated patients are alive after eight years, highlighting the importance of early mutation screening to optimize clinical outcomes.

Source: Astrazeneca, published under the title "Tagrisso demonstrated unprecedented eight-year landmark surv..." - 14 September 2026

Enhertu: Promising Advances in HER2-Mutant Lung Cancer Treatment

Results from the DESTINY-Lung04 trial reveal that Enhertu significantly improves progression-free survival in patients with HER2-mutant non-small cell lung cancer, offering a new therapeutic option against standard treatments.

Source: Astrazeneca, published under the title "Enhertu demonstrated a median progression-free survival of 1..." - 14 September 2026

GSK Unveils Promising Data for Jideytro in Lung Cancer Treatment

GSK has presented encouraging results for Jideytro (zidesamtinib) from a clinical trial, showing a 94% objective response rate in patients with ROS1-positive non-small cell lung cancer. These results could support a regulatory approval application in the United States for first-line treatment, with significant implications for managing this aggressive disease.

Source: Gsk, published under the title "GSK presents positive registrational data to potentially exp..." - 14 September 2026

Ris-Rez: 54% Reduction in Lung Cancer Mortality Risk

The results of the ARTEMIS-008 trial show that Ris-Rez offers a median survival of 18.5 months, surpassing topotecan, while presenting fewer severe side effects. GSK continues to develop this promising treatment for lung cancer and other solid tumors.

Source: Gsk, published under the title "Ris-Rez reduced risk of death by 54% versus topotecan in pat..." - 13 September 2026

Update on the SERENA-4 Phase III Trial of Etcamah with Palbociclib

This announcement contains privileged information regarding the Phase III clinical trial of Etcamah, a promising treatment for advanced ER-positive breast cancer, in combination with palbociclib, aimed at enhancing first-line therapeutic options for patients.

Source: Astrazeneca, published under the title "Update on SERENA-4 Phase III trial of Etcamah in combination..." - 12 September 2026

Johnson & Johnson Unveils Advances on RYBREVANT at WCLC 2026

At the 2026 World Conference on Lung Cancer, Johnson & Johnson will showcase crucial data on RYBREVANT and RYBREVANT FASPRO, highlighting their impact on the survival of patients with non-small cell lung cancer (NSCLC) with EGFR mutations. The results will include analyses of overall survival and treatment-related events, reinforcing the clinical potential of these innovative therapies. RYBREVANT FASPRO, approved for subcutaneous use, represents a significant advancement in the treatment of adults with EGFR-mutated NSCLC, with prophylactic strategies to minimize adverse effects.

Source: J&j - 12 September 2026